Asia On The Move: China Healthcare Reform Head Leaves
This article was originally published in PharmAsia News
Executive Summary
Sun Zhigang is leaving his cabinet position in China to become the deputy head of southwestern Guizhou province, leaving many wondering about the future direction of the massive effort to provide universal health coverage, improve quality and reduce costs for China’s population. Personnel changes are also taking place at Sanofi and Eisai in Japan, GSK in Southeast Asia and the Chinese association Sino-PhiRDA.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.